Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Rs 4 lakh fine on...

    Rs 4 lakh fine on AstraZeneca, 3 ex-officials

    Written by Ruby Khatun Khatun Published On 2018-05-24T15:15:20+05:30  |  Updated On 24 May 2018 3:15 PM IST
    Rs 4 lakh fine on AstraZeneca, 3 ex-officials

    New Delhi: Markets regulator, SEBI on Wednesday imposed a total penalty of Rs 4 lakh on AstraZeneca PharmaIndia and its three former senior officials for not complying with insider trading norms.


    The officials are Lars Walan, Supriya Kumar Guha, and Pawan Singhal.


    Walan was the managing director of AstraZeneca Pharma India from March 29, 2001, to April 1, 2004, and Guha was company secretary/compliance officer of the firm from July 1, 1999, to January 31, 2006. Singhal was the company secretary/ compliance officer of the firm from May 7, 2012, to July 31, 2014.


    According to a Sebi order, the model code of conduct for prevention of insider trading that was mandated to be framed and adopted under the amendment dated February 20, 2002, to the PIT Regulations was adopted by AstraZeneca Pharma India only on February 24, 2004.


    In its order, the regulator said Walan and Guha "had awareness and significant role in framing and adopting the model code of conduct and are liable for the said delay in adopting the same".


    AstraZeneca Pharma India, Walan and Guha "have failed to frame, adopt and implement the code of conduct" as specified in PIT (Prevention of Insider Trading) Regulations till February 24, 2004, and violated the same, Sebi said.


    On March 1, 2014, AstraZeneca Pharma India had informed the exchanges that its board of directors had received a communication from its promoter AstraZeneca Pharmaceuticals AB Sweden, proposing to make a voluntary delisting offer to the public shareholders of the firm.


    As March 1 and 2, 2014 were trading holidays, the information was made public by the exchanges on March 3, 2014, before trading hours.


    Noting that the information pertaining to the delisting had the effect on the price and volume of the scrip of the firm on the next trading day, Sebi said, in such a circumstance, the 24 hours prescription for closing trading window as per the norms must have been followed.


    The non-closure of the trading window on March 3, 2014, was in gross violation of the model code of conduct, the regulator said.


    Under the model code of conduct, among others, the compliance officer is responsible for setting forth policies, procedures, monitoring adherence to the rules for the preservation of the price sensitive information.


    Being the compliance officer of the company during the concerned period, Singhal violated the model code of conduct specified under the PIT Regulations.


    For the violations, the Securities and Exchange Board of India (Sebi) has imposed a penalty of Rs 1 lakh each on AstraZeneca Pharma India, Walan, Guha, and Singhal.

    AstraZeneca PharmaAstraZeneca Pharma Indiafinesformer senior officialsManaging directorPawan SinghalpenaltyPrevention of Insider TradingSEBISecurities and Exchange Board of IndiaSupriya Kumar Guhatrading normsviolations
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok